Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Kidney Cancer Treatment Market By Treatment, By Class of drugs, By Distribution Channel and Geography
Kidney Cancer Treatment Market size was valued at US$ 6,332.8 million in 2023 and is poised to grow at a CAGR of 6.6% during 2024-2030. The kidney cancer treatment market refers to the market for developing therapeutics and treatment options specifically targeted at kidney cancer, also known as renal cell carcinoma (RCC). Kidney cancer is a type of cancer that originates in the kidneys, which are responsible for filtering waste from the blood and producing urine. It is a kind of cancer that is rather prevalent, with regional variations in incidence rates. The kidney cancer treatment market encompasses a broad variety of treatment modalities, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and combination therapies. These therapies aim to stop or at least limit the proliferation of cancer cells, stop the disease from spreading, and enhance the patient’s quality of life. The kidney cancer treatment market is primarily driven by the increasing incidence and prevalence of kidney cancer worldwide.
According to the World Cancer Research Journal, kidney cancer causes 144,000 deaths and 338,000 new cases worldwide each year. Other factors that support the expansion of the kidney cancer treatment market include improvements in diagnostic procedures like computed tomography (CT) scans and magnetic resonance imaging (MRI), the creation of novel and targeted therapies like tyrosine kinase inhibitors and immune checkpoint inhibitors, and increase in research and development activities. Moreover, development of immunotherapy in kidney cancer treatment, adoption of minimally invasive surgical techniques and biomarker-based diagnosis and treatment crate favourable environment for the growth of the kidney cancer treatment market in the forecasting years.
However, expensive kidney cancer treatment, especially when considering the cost of surgeries, targeted therapies, immunotherapies, and follow-up care can limit the access to advanced treatment options for some patients in regions with limited healthcare resources impede the kidney cancer treatment market. Various pharmaceutical companies are introducing innovative treatment options and advancements in medical technology to further contribute to market growth. For instance, in November 2021, Merck’s KEYTRUDA (pembrolizumab) got FDA approval as adjuvant therapy for patients with renal cell carcinoma (RCC) following surgery.
Study Period
2024-2030Base Year
2023CAGR
6.6%Largest Market
North AmericaFastest Growing Market
Asia Pacific
kidney cancer treatment market is expected to grow at significant rates owing to the factors such as increase in prevalence of kidney cancer due to the lifestyle changes and increase in smoking and consuming alcohol. In addition, increase in geriatric population who are more prone to the kidney related diseases coupled with the increase in R&D support and investments by the government in screening of cancer and in development of new treatment of drugs. Furthermore, availability of kidney cancer treating drugs are low, it is likely to act as growth opportunity for development of new drug treatments for the treatment. However, high prices of available branded drugs for the treatment of kidney cancer and high R&D expenditure for the development of new drugs are expected to hinder the market growth over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 6,332.8 million |
Market CAGR |
6.6% |
By Treatment |
|
By Drug Class |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global kidney cancer treatment market size was valued at US$ 6,332.8 million in 2023 and is expected to grow at a CAGR of 6.6% from 2024 to 2030.
The kidney cancer treatment market key players are Abbott Laboratories, Amgen Inc., Bayer AG, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck KGaA (EMD Serono), Novartis International AG
Asia Pacific is the fastest-growing region in the kidney cancer treatment market
Key Market Players